Tumors with BRAF and NRAS Mutations
This condition refers to tumors that have specific genetic mutations in the BRAF or NRAS genes, which can influence treatment options and outcomes.
KIN-2787: New Oral Drug for Cancer
We are studying the safety and effects of KIN-2787 in patients with BRAF and/or NRAS mutation-positive solid tumors. This research aims to find out how well this new treatment works.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Institut Bergonie
Medical Oncology
Bordeaux, France
Centre Francois Baclesse
Oncology Department
Caen, France
Centre Hospitalier Universitaire De Lille
Oncology Department
Loos, France
Sponsor: Pierre Fabre Medicament
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.